10-Q: Milestone Scientific Reports Mixed Q2 Results Amidst Strategic Shifts

Milestone Scientific's Q2 2024 results show a decrease in revenue compared to the previous year, but also a significant gain from the sale of net operating losses.

Summary

• Milestone Scientific reported a net income of $223,638 for the second quarter of 2024, a significant turnaround from a net loss of $2,228,828 in the same period last year.
• The company's revenue decreased to $1.85 million in Q2 2024 from $2.91 million in Q2 2023, primarily due to a decline in international sales and the termination of a US distributor.
• Gross profit also decreased to $1.41 million in Q2 2024 from $1.89 million in Q2 2023.
• Operating expenses decreased to $3.19 million in Q2 2024 from $4.17 million in Q2 2023, mainly due to lower employee salaries and benefits, marketing, and royalties expenses.
• The company recorded a gain of $1.98 million from the sale of New Jersey net operating losses.
• For the six months ended June 30, 2024, the company reported a net loss of $1.22 million, compared to a net loss of $3.55 million for the same period in 2023.
• Cash and cash equivalents increased to $5.75 million as of June 30, 2024, from $2.98 million at the end of 2023.
• The company's working capital was approximately $7.7 million as of June 30, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company achieved a net income in Q2 and improved its cash position, the revenue decline and reliance on future capital raises temper the positive aspects. The regulatory approvals and Medicare assignments are positive, but the overall financial performance is still concerning.

Positives

• The company achieved a net income in Q2 2024, a significant improvement from the previous year.
• Cash and cash equivalents have increased substantially, providing a stronger financial position.
• The sale of net operating losses generated a significant gain, boosting the bottom line.
• Operating expenses have been reduced, indicating improved cost management.
• The e-commerce platform is contributing a significant portion of the company's revenue.
• Regulatory approvals in Brazil and favorable Medicare assignments in Florida expand market opportunities for the CompuFlo Epidural System.

Negatives

• Revenue decreased by approximately $1.1 million in Q2 2024 compared to Q2 2023.
• Gross profit decreased by approximately $479,000 in Q2 2024 compared to Q2 2023.
• International sales experienced a significant decline in Q2 2024.
• The company recorded no revenue from China in Q2 2024.
• The company recorded an allowance for medical inventory due to slow commercialization.

Risks

• The company's continued operations depend on its ability to raise additional capital.
• The company relies on third-party manufacturers, and any disruption could negatively impact production.
• The company faces risks related to international sales and operations, including in China.
• Changes in distribution arrangements could interrupt marketing efforts.
• The company's products may become obsolete or non-competitive due to competitor developments.
• The company is subject to risks of interruption of marketing efforts and building new marketing channels.

Future Outlook

The company is actively pursuing positive cash flows through increased revenue from its dental and medical businesses and reduced operating expenses, but its continued operations depend on its ability to raise additional capital until it achieves profitability.

Management Comments

• Milestone Scientific remains focused on advancing efforts to achieve the following three primary objectives: Establishing Milestones DPS Dynamic Pressure Sensing technology platform as the standard-of-care in painless and precise drug delivery, providing for the first time, objective visual and audible in-tissue pressure feedback, and continuing to expand platform applications; Following obtaining successful FDA clearance of our first medical device, Milestone Scientific is transitioning from a research and development organization to a commercially focused medical device company; and Expanding our global footprint of our CompuFlo Epidural and CathCheck System by utilizing a targeted field sales force and partnering with distribution companies worldwide.

Industry Context

The company is operating in the medical and dental device industry, which is characterized by innovation and regulatory hurdles. The company's focus on computer-controlled injection technology positions it in a niche market with potential for growth, especially with the recent regulatory approvals and Medicare assignments.

Comparison to Industry Standards

• Milestone Scientific's revenue decline contrasts with the growth seen in some other medical device companies, such as Stryker and Medtronic, which have reported revenue increases in recent quarters.
• The company's gross profit margin of approximately 76% is within the range of other medical device companies, but the decrease from the previous year is a concern.
• The company's operating expenses are relatively high compared to its revenue, indicating a need for improved cost management.
• The company's cash position has improved, but it still needs to raise additional capital to achieve profitability, which is a common challenge for early-stage medical device companies.
• The company's regulatory approvals in Brazil and favorable Medicare assignments in Florida are positive developments that could help it compete with larger players in the market.

Related Party Transactions

• Milestone Scientific has a supply agreement with United Systems, whose controlling shareholder is a significant stockholder of Milestone Scientific.
• The Director of Clinical Affairs received royalty fees and consulting fees from Milestone Scientific.
• Leonard Osser, a director, has a Royalty Sharing Agreement and a Succession Agreement with the company.
• The University Pain Medicine Center (STEMMEE), of which Dr. D. Demesmin, a Company board member is the CEO, purchased products from the Company.

Stakeholder Impact

• Shareholders may be concerned about the revenue decline but encouraged by the net income and improved cash position.
• Employees may be affected by the company's cost-cutting measures, including reduced salaries and benefits.
• Customers may benefit from the company's innovative products and expanded market reach.
• Suppliers may be affected by the company's reliance on third-party manufacturers and potential disruptions.
• Creditors may be concerned about the company's reliance on future capital raises.

Next Steps

• The company intends to continue to expand the uses and applications of its DPS Dynamic Pressure Sensing technology.
• The company is focused on transitioning from a research and development organization to a commercially focused medical device company.
• The company plans to expand its global footprint of its CompuFlo Epidural and CathCheck System by utilizing a targeted field sales force and partnering with distribution companies worldwide.

Key Dates

Keywords

Milestone Scientific, CompuFlo, STA Single Tooth Anesthesia System, epidural, anesthesia, medical devices, dental, revenue, net income, operating expenses, e-commerce, regulatory approval, Medicare, handpieces, injections